This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
News|Articles|September 22, 2015
PTSM: Pharmaceutical Technology Sourcing and Management
- PTSM: Pharmaceutical Technology Sourcing and Management-10-07-2015
- Volume 11
- Issue 10
ReposiTrak Announces Track and Trace Agreement
Author(s)Pharmaceutical Technology Editors
ReposiTrak signs agreement to pilot track and trace system in pharma.
Advertisement
Park City Group’s ReposiTrak has signed an agreement with a biopharmaceutical manufacturer to pilot ReposiTrak’s Track & Trace solution. ReposiTrak will provide the manufacturer with visibility to product movement through the supply chain and guard against the entry of counterfeit drugs.
Using the company’s Track & Trace system, the biopharmaceutical manufacturer will track the end-to-end movement of items at the lot level. Trading partners will receive alerts to any unauthorized movement or location to ensure product authenticity and eliminate the entry of counterfeits. Once the efficacy of ReposiTrak’s Track & Trace system has been proven, the manufacturer plans to leverage the technology’s scalability and launch a full rollout.
Source:
Articles in this issue
about 11 years ago
Cost Inhibits CMO Adoption of Single-Use Equipmentabout 11 years ago
Low Temperature Needed for Complex Drug Candidatesabout 11 years ago
FDA Plans Pilot Projects for Drug Supply Chain Security Actabout 11 years ago
Vetter Embarks on 300-Million Euro Manufacturing Expansionabout 11 years ago
Sterigenics International Adds Capacityabout 11 years ago
Tecnandina’s Ecuador Facility Receives ANVISA Certificationabout 11 years ago
Hovione Expands Drug Substance Manufacturingabout 11 years ago
Piramal Introduces Proof of Concept Service for Next Wave of ADC Growthabout 11 years ago
Patheon Unveils New Brand Identityabout 11 years ago
FDA Releases Guidance on Generic-Drug DevelopmentAdvertisement
Related to this article
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Mitigating nitrosamine risk requires assessing each product individually, says Bram Baert, Global Head of Regulatory Affairs at Capsugel, and Sandrine Picco, Senior Analytical Specialist on Capsugel's Innovaform Accelerator Team, in this interview with PharmTech.
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Ronald Piervincenzi, USP, urges drugmakers and purchasers to act on supply chain resilience to curb drug shortages and shape better policy.
Content on PharmTech.com this week ranged from fundamentals on the use of digital pathology in drug development, discussions on the use of AI in pharma, and regulatory actions impacting the industry.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Pritelivir Shifts Resistant Herpes Care from Intravenous to Oral
2
What the Olanzapine Depot Approval Means for CMC Teams
3
PharmTech AI Pulse Check: Availability Bias Threatens AI Regulatory Reviews
4
Complying with International Pharmacopoeias
5